Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-102 in Diabetic Foot Infection
2023-507716-13-00Phase 2Completed
- Sponsor
- TechnoPhage
- Start
- Jan 2024
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in diabetic foot infection (DFI), diabetic foot ulcer (DFU), Acinetobacter baumannii infection and 2 more comparing TP-102 + SoC with Placebo + SoC (2 arms). Primary endpoints: Treatment Emergent Adverse Events, Change in IWGDF/IDSA Infection Class and 1 more. Started Jan 2024; status: completed.
02
Drugs
TP-102
03
Conditions
diabetic foot infection (DFI)diabetic foot ulcer (DFU)Acinetobacter baumannii infectionPseudomonal infectionStaphylococcus aureus infection
Beyond the preview
Go deeper on 2023-507716-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507716-13-00.